Geron Corporation Shares Plunge Following Decision to Halt Imetelstat Clinical Trial
Geron Corporation (GERN) shares fell by more than 20% on Wednesday after the company announced it would discontinue a late-stage clinical trial for its lead asset, imetelstat (marketed as Rytelo). The decision follows emerging concerns regarding the drug's efficacy in patients. The halt of this pivotal trial represents a significant setback for the cancer drugmaker, as imetelstat is central to Geron's long-term growth strategy. Investors reacted sharply to the news, reflecting uncertainty surrounding the company's primary development pipeline and future regulatory prospects.
Tickers: $GERN
Topics: clinical trial discontinuation drug efficacy stock price drop
Read the full article at Seeking Alpha
Part of the story Geron Corporation Shares Plunge Following Decision to Halt Imetelstat Clinical Trial (2 articles)